Abbott closes Kos acquisition
Executive Summary
Abbott completes its $3.7 billion cash purchase of Kos Pharmaceuticals in just thirty business days, CFO Thomas Freyman announces during the JP Morgan Healthcare Conference Jan. 9. The deal, proposed by Abbott in early November, will help diversify the firm's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases (1"The Pink Sheet" Nov. 13, 2006, p. 13)...
You may also be interested in...
Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition
Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.